Get the Stockscreener App
1.06
3.92%
0.04
Lisata Therapeutics Inc stock is traded at $1.06, with a volume of 13,714.
It is up +3.92% in the last 24 hours and down -31.17% over the past month.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
See More
Previous Close:
$1.02
Open:
$1.05
24h Volume:
13,714
Relative Volume:
0.08
Market Cap:
$11.45M
Revenue:
$170.00K
Net Income/Loss:
$-16.35M
P/E Ratio:
-0.5697
EPS:
-1.8605
Net Cash Flow:
$-13.66M
1W Performance:
-11.67%
1M Performance:
-31.17%
6M Performance:
-73.57%
1Y Performance:
-56.38%
1-Day Range:
$1.00
$1.06
1-Week Range:
$0.98
$1.28
52-Week Range:
$0.98
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
1.06 | 11.45M | 170.00K | -16.35M | -13.66M | -1.8605 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Form PRE 14A Lisata Therapeutics For: 7 October By Investing.com - Investing.com India
A rare hormone disorder trial doses its first patient; its drug may allow shots every two weeks, not daily. - Stock Titan
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Lisata director holds preferred tied to 2.27M shares - Stock Titan
Lisata COO Holds Preferred Stock Tied to 2.54M Shares - Stock Titan
Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it? - Yahoo Finance
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz - Pharmaceutical Executive
Lisata Therapeutics Acquires Marea, Refocuses on Cardioendocrine Portfolio - The Globe and Mail
Why Is Lisata Therapeutics (NASDAQ:LSTA) Becoming A Penny Stocks Test? - Kalkine Media
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement - Yahoo! Finance Canada
Lisata Therapeutics acquires Marea, raises $225 million - Investing.com
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement - GlobeNewswire
Lisata Therapeutics Acquires Marea Therapeutics in $225 Million Financing to Advance Cardioendocrine Pipeline - Quiver Quantitative
Lisata Therapeutics Acquires Marea Therapeutics in $225 Million Financing to Advance Cardioendocrine Pipeline - Quiver Quantitative
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement - Yahoo Finance
3 Promising Penny Stocks With At Least $10M Market Cap - Sahm
3 Promising Penny Stocks With At Least $10M Market Cap - simplywall.st
Single investor holds 5% slice of Lisata Therapeutics (LSTA) - Stock Titan
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price, LSTA Stock News, LSTA Share Price & Updates - kalkine.ca
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Lisata (LSTA) Trading Levels Update: Climbs 6.48% to $1.15 in the Latest Session; Technical Focus: $1.09 and $1.21 Define the Nearby Reference LevelsHull Moving Average - vinanet.vn
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – FWB:8NE - TradingView
Lisata Therapeutics (LSTA) Drops 4.24% to $1.13, Approaching Critical SupportBlue Chip Entry Points - Vinanet
Enterprise value to EBITDA forward of Lisata Therapeutics, Inc. – SWB:8NE - TradingView
Lisata Therapeutics (LSTA) Slides 2.48% as Biotech Stock Holds Key SupportScalping Stock Signals - dars.gov.et
Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
Lisata Therapeutics (8NE) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Lisata Therapeutics Inc. (NASDAQ: LSTA) Share Price, LSTA Stock News, LSTA Share Price & Updates - Kalkine
Lisata Therapeutics (LSTA) Slips 0.93% as Shares Hover Near Key Support at $1.02Money Flow - vinanet.vn
LISATA THERAPEUTICS, INC. 2026: Revenue $0 EPS ($0.32) — 10-Q Summary - TradingView
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment - The Globe and Mail
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment - TipRanks
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce By Investing.com - Investing.com India
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce - Investing.com
Lisata Therapeutics, Inc. Continues to Evaluate Strategic Alternatives to Enhance Stockholder Value - marketscreener.com
Lisata Therapeutics (LSTA) Pursues Legal Action After Merger Ter - GuruFocus
Lisata Therapeutics, Inc. (LSTA) Files 8-K Announcing Retention Bonus Agreement With James Nisco - Minichart
Lisata Therapeutics Files Suit Against Kuva Labs, Reviews Strategic Alternatives and Cuts Workforce to Preserve Cash - Quiver Quantitative
Lisata Therapeutics sues Kuva Labs, cuts 72% of workforce By Investing.com - Investing.com UK
Lisata Therapeutics, Inc. Implements a Reduction in Force, Eliminating Approximately 72% of Full-Time Employees - marketscreener.com
Lisata Therapeutics terminates Dr. Kristen K. Buck as EVP R&D & CMO; James Nisco awarded $200,000 retention bonus - TradingView
Lisata Therapeutics moves forward with legal action following Kuva merger termination - Proactive financial news
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
Lisata Therapeutics (LSTA) Drops 3.9% to $0.99 as Biotech Stock Presses Key SupportOrder Block - dars.gov.et
LSTA Q3 2025 Earnings: Narrower-than-Expected Loss Offers Modest Encouragement Despite Share DipEPS Surprise History - vinanet.vn
Lisata Therapeutics, Inc. Revenue Breakdown – NASDAQ:LSTA - TradingView
Kuva Labs (LSTA) ends Lisata cash-and-CVR tender offer after financing shortfall - Stock Titan
Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lisata Therapeutics Inc (LSTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):